All sponsors

Jazz Pharmaceuticals $JAZZ

Clinical trial pipeline · active industry-sponsored Phase 1/2 to Phase 3 trials · updated 2026-11-18
ACTIVE TRIALS13
PHASE 3 / 2-37
RECRUITING12
READOUTS ≤12 MONTHS1
READOUT SLIPPED >6 MO43%

Delay Index: of 7 active trials registered more than a year ago, 3 have moved their primary completion (readout) date by more than 6 months since first registration (median +5.0 months). See all sponsors →

Open Jazz Pharmaceuticals on the live radar map → 📅 $JAZZ readout calendar (.ics)
TRIALPHASESTATUSCONDITIONNPRIMARY COMPLETION
HERIZON-GEA-01
NCT05152147
P3Active, not recruitingGastric Neoplasms; Gastroesophageal Adenocarcinoma9202026-07-15 (+25 mo)
Zanidatamab
NCT06695845
P2RecruitingBreast Cancer; Gastric Cancer2002026-12-31
XYRISE
NCT07625280
P3RecruitingNarcolepsy; Idiopathic Hypersomnia1202027-12-23
EmpowHER 208
NCT07102381
P2RecruitingHER2-positive Breast Cancer; Breast Cancer1252027-12-29
Lurbinectedin
NCT05734066
P1/2RecruitingRefractory Ewing Sarcoma; Relapsed Ewing Sarcoma602028-01-28 (+14 mo)
Zanidatamab
NCT06435429
P3RecruitingMetastatic HER2-positive Breast Cancer5502028-04-28 (-36 mo)
ACTION
NCT05580562
P3RecruitingH3 K27M; Glioma5102028-06 (+22 mo)
JZP926 capsule
NCT07723963
P2/3RecruitingJuvenile Myoclonic Epilepsy2602028-08-01
JZP3507
NCT07533942
P2RecruitingMeningioma302028-10-25
Zanidatamab
NCT06282575
P3RecruitingBiliary Tract Cancer2862028-12-01 (+5 mo)
ONC206
NCT07282587
P2RecruitingAdvanced Pheochromocytoma and Paraganglioma; PCPG902028-12-15
Lurbinectedin
NCT07459634
P2RecruitingExtensive-stage Small-cell Lung Cancer502029-08-04
CBD-OS
NCT07723976
P3RecruitingDevelopmental and Epileptic Encephalopathy (DEE)1202029-09-04